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doi:10.1016/j.jfma.2012.04.004Background/Purpose: Connective tissue growth factor (CTGF/CCN2) is involved in the develop-
ment and progression of fibrotic diseases, including gingival overgrowth (GO). Recent studies
indicate that lysophosphatidic acid (LPA) is also significantly involved in wound healing and
the development of fibrosis. This study investigated whether epigallocatechin-3-gallate
(EGCG) can inhibit LPA-induced CCN2 expression in human gingival fibroblast (GF) and its
mechanism.
Methods: Western blot analyses were used to study the signaling pathways of LPA-induced
CCN2 expression in human GFs and the effects of EGCG on this pathway.
Results: LPA stimulated CCN2 synthesis in human GFs. This effect can be significantly inhibited
bytransforming growth factor-b type I receptor/ALK5, Smad3, and JNK inhibitors but not ERK,
P38, and MAPK inhibitors. EGCG completely inhibited LPA-induced CCN2 expression through
attenuating the LPA-induced JNK and Smad3 phosphorylation in human GFs.
Conclusion: LPA produced at the surgical wound may contribute to the recurrence of GO by
upregulating CCN2 expression in human GFs. This effect was mediated by Smad3 and JNK acti-
vation and ALK5 transactivation. EGCG could be a useful agent for reducing the recurrence of
GO after surgery through suppression of JNK and Smad3 activations.
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Epigallocatechin-3-gallate inhibits LPA-stimulated CTGF 51Introduction fibrosis.22 LPA induces CCN2 expression in a variety of cell
12Gingival overgrowth (GO) is characterized by the accumu-
lation of excessive connective tissue and extracellular
matrix (ECM) in gingival tissues. The most recognized GO is
drug-induced gingival overgrowth (DIGO), which is a side
effect of the administration of three groups of medica-
ments: anticonvulsants (phenytoin), immunosuppressants
(cyclosporin A), and calcium channel blockers (nifedipine,
verapamil, diltiazem).1,2 Although surgical treatment is the
most definitive therapy for DIGO, the recurrence rate of
DIGO is high (34%) after surgical excision.3 A potential
mechanism for the rapid regrowth of gingival tissues is the
early recruitment of platelets and coagulation factors to
the surgical wound.4 However, the mediators directing
these pathologic responses have yet to be fully identified.
Better identification of the mediators linking surgical
wound healing and rapid regrowth of gingival tissues after
surgery is needed to develop new therapeutic strategies for
the treatment of DIGO.
A number of mediators such as growth factors, cyto-
kines, and chemokines have been found to play a role in
the development of tissue fibrosis. Transforming growth
factor-b (TGF-b), the most fibrogenic mediator identified
to date, has been suggested as the main trigger for both
the increased collagen production and decreased matrix
degradation in tissue fibrosis.5 However, TGF-b is also
involved in immunosuppression and tumor suppression.6
Broadly suppressing TGF-b action could adversely affect
the treatment of chronic disorders such as fibrosis.
Recently, a neutralizing anti-TGF-b antibody (CAT-192) has
been used in a multicenter clinical trial for patients with
systemic sclerosis patients with no efficacy, but with
increased mortality and serious adverse effects.7
Connective tissue growth factor (CTGF), or CCN2, is
a 38-kDa secreted protein belonging to the CCN protein
family.8 It regulates diverse biologic effects such as cell
adhesion, migration, proliferation, and ECM production and
plays important roles in wound healing. CCN2 over-
expression has been widely shown to associate with the
onset and progression of pulmonary,9 renal,10 hepatic,11
and gingival fibrosis.12 It creates an environment favor-
able for fibrosis13 and is required for the maximal profi-
brotic effects of TGF-b.14,15 Blockade of CCN2 by anti-CCN2
antibodies or by antisense messenger RNA inhibits both
CCN2-mediated and TGF-b-mediated ECM production
in vitro and in vivo.16 In adults, CCN2 is only produced by
hepatic stellate and kidney mesangial cells. Thus, CCN2
may serve as a target for the treatment of tissue fibrosis.
Recent studies indicate that lysophosphatidic acid (LPA)
is significantly involved in wound healing and the develop-
ment of fibrosis.17 Increased release of LPA is observed in
tissue injury, inflammation, and neoplasia.18 High levels of
LPA (1-5 mM) are detectable inserum and are attributed to
their release from activated platelet.19 It regulates diverse
cellular functions such as cell adhesion, migration, and
proliferation in fibroblasts.20 Most cellular effects of the
LPA are mediated by the LPA class of G protein-coupled
receptors (GPCRs).21 Currently five G protein-coupled
receptors have been identified as specific for LPA (desig-
nated LPAR1e5). LPAR1 has been shown to be involved inmediating the development of bleomycin-induced lung
types including gingival epithelial cells and fibroblasts.
Gan et al23 showed that the LPA-LPAR-CCN2 signaling
pathway is involved in the development of radiation lung
fibrosis (RLF).23 Blockade of CCN2 by small interfering RNA
is directed against CCN2-alleviated RLF. CCN2 may also play
an important role in LPA-mediated fibrosis.
Although a growing number of profibrotic mediators and
pathways have been reported, there are very few anti-
fibrotic molecules currently being evaluated in clinical
trials. We recently found that curcumin effectively inhibits
arecoline-induced CCN2 synthesis in buccal mucosal fibro-
blasts (BMFs).24 Epigallocatechin-3-gallate (EGCG),the
major polyphenol found in green tea, completely inhibited
thrombin-induced CCN2 synthesis in BMFs.25 Therefore, we
investigated whether curcumin or EGCG affected the LPA-
stimulated induction of CCN2 in human gingival fibroblasts
(GFs). The underlying mechanism of the CCN2 inhibition
was further examined.
Materials and methods
Materials
LPA, EGCG, and curcumin were from Sigma-Aldrich Co.
(St. Louis, MO, USA). Specific inhibitor of TGF-b type I
receptor/activin receptor-like kinase 5 (ALK5) SB431542,
Smad3 phosphorylation inhibitor SIS3, extracellular
signal-regulated kinase (ERK) inhibitor PD98059, c-Jun NH2-
terminal kinase (JNK) inhibitor SP600125, and p38 mitogen-
activated protein kinase (MAPK) inhibitor SB203580 were
from Calbiochem(San Diego, CA, USA). Goat anti-CCN2
polyclonal antibody (sc-14939), rabbit antitotal JNK poly-
clonal antibody (sc-571), andmouse anti-b-actinmonoclonal
antibody (sc-47778) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit antibodies against phospho-
JNK (#9251), Smad3 (#9523), and phosphor-Smad3 (9520)
antibodies were purchased from Cell Signaling (Beverly, MA,
USA). Donkey antigoat or goat antimouse horseradish
peroxidase-link secondary antibodies were from Jackson
ImmunoResearch Laboratories (West Grove, PA, USA). All
tissue culture biologic agents were obtained from Invitrogen
(Carlsbad, CA, USA).
Cell culture
After receiving the approval of theHospitalEthics Committee,
human gingival tissueswere obtained from four patients
during periodontal flap surgery with informed consent from
the patients. Four primary human GF cultures were estab-
lished by an explant technique as described previously.24,25
Briefly, tissues were cut into 1 mm1 mm explants and
cultured in Dulbecco modified Eagle medium (DMEM)
with 10% fetal calf serum (FCS), 100 U/mL penicillin, and
100 mg/mL streptomycin at 37C in an incubator with 5%
CO2 and humidified air. After 3e7 days, there were cells
outgrown from the explants. When the outgrowth of GFs
was near confluence, cells were subcultured in a ratio of
1:3. Cells between 4 and 10 passages were plated on 60-mm
Petri dishes at a density of 2  105 cells and subjected to
various treatments. Before treatment, the cells were
Figure 1 Lysophosphatidic acid (LPA) stimulated CCN2
expression in human gingival fibroblasts (GFs). (A) Cells were
treated with various concentrations (0 to 20 mM) of LPA for 4
hours. CCN2 protein levels were measured by Western blot
analysis. (B) Kinetics of CCN2 induction by 15 mM LPA in GFs.
52 C.-Y. Wang et al.incubated in serum-free media for 18 hours. In selected
experiments, five groups of GFs were pretreated with
10 mM of ALK5 inhibitor SB431542, 10 mM of Smad3
inhibitor SIS3, 10 mM of ERK inhibitor PD98059, 10 mM of JNK
inhibitor SP600125, or 10 mM of p38 MAP kinase inhibitor
SB203580 (Calbiochem) for 1 hour before exposure to 15 mM
LPA for 4 hours. Data given herein are the means of four
experiments.
Western blot analysis
Western blot analysis was performed as previously
described.24,25 In brief, cells were harvested, lysed in lysis
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40,
1 mM EDTA, 50 mg/ml leupeptin, 30 mg/ml aprotinin,
1 mM phenylmethylsulfonyl fluoride), separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and
transferred to Polyvinylidene difluoride (PVDF) membrane.
The membrane was then incubated with antibodies against
CCN2 (1:1000), b-actin (1:1000), phosphor-JNK (1:750),
total JNK (1:1000), phosphor-Smad3, and Smad3 (1:1000).Figure 2 Effects of various inhibitors on the LPA-induced CCN2 e
ALK5 inhibitor SB431542, 10 mM of Smad3 inhibitor SIS3, 10 mM of ER
of p38 MAP kinase inhibitor SB203580 for 1 hour, then treated with
blot analysis. (B) Results of (A) were quantified using densitometric
fold change relative to untreated controls. Data are presented as m
with control, )p < 0.05 compared to 15 mM LPA).Primary antibodies were detected with donkey antigoat or
goat antimouse horseradish peroxidase-link secondary
antibodies (1:10000). For quantitative analysis, we added
the Western Lighting Chemiluminescence Reagent Perki-
nElmer Inc., Waltham, MA, USA on the membrane and
analysis was done with a Fuji LAS-4000 lumino image
analyzer (Fuji Photo Film Co., Tokyo, Japan).
Statistical analysis
Group data are expressed as mean  standard error of the
mean. The unpaired Student ttest (for control and study
group comparisons) was applied to compare group differ-
ences. In addition, p <0.05 was considered statistically
significant.Results
Human GFs were first treated with various concentrations
of LPA. As shown in Fig. 1A, LPA significantly increased
CCN2 synthesis. The levels of CCN2 protein increased
approximately threefold after 4 hours of exposure to 15 mM
LPA. We then treated GFs with 15 mM LPA for various
incubation periods to study the kinetics of LPA-induced
CCN2 synthesis. Fig. 1B showed that the peak level of
CCN2 in GFs treated with 15 mM LPA occurred at 4 hours and
declined thereafter.
To investigate the signal transduction pathways involved
in LPA-induced CCN2 expression in GFs, cells were pre-
treated with 10 mM of ALK5 inhibitor SB431542, 10 mM of
Smad3 inhibitor SIS3, 10 mM of ERK inhibitor PD98059, 10 mM
of JNK inhibitor SP600125, or 10 mM of p38 MAP kinase
inhibitor SB203580 for 1 hour before exposure to 15 mM LPA
for 4 hours. The results of Western blots demonstrated
that SB431542, SIS3, and SP600125 reduced approximately
73.7%, 89.4%, and 99.1%, respectively, of the LPA-induced
levels of CCN2 protein (Fig. 2). However, PD98059 and
SB203580 had no significant effect on the LPA-induced CCN2
protein expression.xpression in human GFs. (A) GFs were pretreated with 10 mM of
K inhibitor PD98059, 10 mM of JNK inhibitor SP600125, or 10 mM
15 mM LPAfor 4 hours. CCN2 levels were measured by Western
analysis, normalized by the level of b-actin, and expressed as
eans  standard error of the mean (nZ 4, #p < 0.05 compared
Figure 3 Epigallocatechin-3-gallate (EGCG) and curcumin
inhibited lysophosphatidic acid (LPA)-induced CCN2 expression
in human gingival fibroblasts (GFs). Cells were pretreated with
(A) 20 mM curcumin, 20 mM EGCG, or (B) increasing concen-
trations of EGCG (0-20 mM) for 1 hour, then treated with 15 mM
LPAfor 4 hours. CCN2 levels were measured by Western blot
analysis.
Epigallocatechin-3-gallate inhibits LPA-stimulated CTGF 53We further investigated whether curcumin or EGCG
could affect LPA-induced CCN2 expression in human GFs.
As shown in Fig. 3A, 20 mM curcumin and 20 mM EGCG
inhibited approximately 58% and 96%, respectively, of the
LPA-induced CCN2 expression. Furthermore, EGCG inhibi-
ted LPA-induced CCN2 expression in a dose-dependent
manner (Fig. 3B). Because 20 mM EGCG almost completely
inhibited LPA-induced CCN2 expression, we examined the
effect of EGCG on the LPA-induced Smad3 and JNK phos-
phorylation. Results revealed that EGCG significantly
attenuated the LPA-induced JNK and Smad3 phosphoryla-
tion (Fig. 4).
Discussion
Elevated levels of CCN2 are found in fibrotic lesions and
suggested to be involved in the development and progres-
sion of fibrotic diseases.8e16 In GO, CCN2 levels correlated
positively with the degree of fibrosis consistent with the
role of CCN2 in promoting and maintaining fibrosis.26
Surgical removal of GO is often necessary when the
gingiva interferes with the chewing function, oral hygieneFigure 4 Epigallocatechin-3-gallate (EGCG) significantly inhibite
JNK and Smad3.maintenance, or esthetics.27 However, the recurrence rate
after surgery is high even under well-controlled periodontal
maintenance.3 It has been shown that LPA induced CCN2
expression in human gingival epithelial cells and fibro-
blasts.12 We also found that LPA induced CCN2 expression in
human GFs. During early postsurgical healing, numerous
activated platelets and coagulation factors were recrui-
tedto the site of surgery to form a stable fibrin. LPA
released from activated platelets may influence the rapid
regrowth of gingival tissues during wound healing through
increased CCN2 expression in human GFs. In certain indi-
viduals, LPA produced at the surgical wound after surgery
might act in concert with other fibrotic mediators to
develop gingival fibrosis.
Multiple signaling pathways have been related to CCN2
gene expression.8,24,25 Identifying the signaling associated
with LPA-induced CCN2 expression in GFs is important in
developing more appropriate antifibrotic strategies for the
drug intervention or chemoprevention of GO. Recent
studies showed that LPA induced CCN2 expression in
gingival fibroblast through the JNK/Smad pathway.4
Cabello-Verrugio et al28 found that CCN2 induction by LPA
requires transactivation of TGF-b receptors and the JNK
pathway in mouse skeletal muscle cell line C2C12. In this
study, LPA-induced CCN2 expression can be significantly
inhibited byALK5, Smad3, and JNK inhibitors but not ERK,
P38, or MAPK inhibitors. Our study is the first to show that
ALK5 inhibitor SB431542 significantly suppresses LPA-
induced CCN2 expression in GFs. No elevation of TGF-b1
messenger RNA levels was found after treatment with LPA
(data not shown). Therefore, LPA-induced CCN2 expression
in GFs, as in C2C12 cells, also requires ALK5 transactivation.
Since ancient times, green tea has been considered by
the traditional Chinese medicine as a healthful beverage.29
The health-promoting effects of green tea are mainly
attributed to EGCG, the most prevalent polyphenol con-
tained in green tea. It is estimated that a cup of green tea
(2.5 g of green tea leaves/200 mL of water) may contain
90 mg of EGCG.30 EGCG has been shown to reduce TGF-
b-induced type I collagen and CCN2 expression in hepatic
stellate cells31 and dermal fibroblasts from systemic sclero-
derma patients.32 We recently found EGCG completely
inhibited thrombin-induced CCN2 synthesis in BMFs.25
Animal studies showed EGCG suppressed methylglyoxal-
induced peritoneal fibrosis,33 injury-induced liver
fibrosis,34 and bleomycin-induced pulmonary fibrosis.35 Thed the lysophosphatidic acid (LPA)-induced phosphorylation of
54 C.-Y. Wang et al.current study showed EGCG completely blocked the
LPA-induced CCN2 expression through inhibition of JNK
and Smad3 activation in GFs. To our knowledge, this is the
first time it has been demonstrated that EGCG can reduce
LPA-stimulated CCN2 production through the suppression
of JNK and Smad3 phosphorylation. Our findings may
provide potentially useful information for the treatment of
gingival fibrosis caused by CCN2 overexpression. Further
research involving animal studies is required to confirm
the role of EGCG in reducing the recurrence of gingival
overgrowth.Acknowledgments
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